Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations
In 2020, Darzalex Faspro (Daratumumab and hyaluronidase-fihj) subcutaneous injection was approved for marketing, reducing the administration time from several hours with intravenous (IV) injection to 3-5 minutes with subcutaneous (SC) injection
NO.10 Skyrizi Company: AbbVie 2024 worldwide sales forecast: $9.93 billion Skyrizi (Risankizumab) is an IL-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit
It also leans into expanding therapeutic uses and making sure treatment is more accessible, for more people
Due to COVID-19, the drug has consistently achieved robust sales since its introduction
Behind the scenes the market leans on active pharmaceutical ingredients, peptide synthesis technologies, biologic manufacturing processes, and better drug delivery systems that keep the effect stable